Two ruthenium compounds, namely [ImH]trans-[RuCl4(Im)(dmso-S)] (NAMI-A, Im = imidazole) and [IndH] trans-[RuCl4(Ind)2] (KP1019, Ind = indazole) have already completed phase I clinical trials as anticancer agents. They both have properties different from platinum anticancer drugs: for example, NAMI-A is selectively active against metastases of solid tumors. They show that in the field of anticancer metal drugs a new approach, based on targeted therapies, is possible. After a concise history of ruthenium anticancer compounds, this contribution will focus on ruthenium-dmso complexes and, in particular, on NAMI-A. Particular emphasis is given on the challenges that are inherent to this field: how to develop new anticancer ruthenium compounds and how to select new active compounds that manifest their anticancer activity through non-conventional mechanisms.

No abstract

With the aim of further developing the structure-activity relationship in biologically active half-sandwich Ru(ii)-[9]aneS(3) complexes ([9]aneS(3)=1,4,7-trithiacyclononane), a series of new mono- and dinuclear complexes bearing the chelating dicarboxylate ligands oxalate (ox), malonate (mal) and methylmalonate (mmal), have been synthesized and studied. Treatment of the precursor [Ru([9]aneS(3))(dmso)(3)][CF(3)SO(3)](2) (7) with equivalent amounts of K(2)(dicarb) afforded the corresponding neutral complexes with the general formula [Ru([9]aneS(3))(dmso-S)(eta(2)-dicarb)] (where dicarb=ox (1), mal (2) and mmal (3)), while using half an equivalent of K(2)(ox), the symmetric dimer [{Ru([9]aneS(3))(dmso-S)}(2)(mu-eta(4)-ox)][CF(3)SO(3)](2) (4) was isolated. The reaction of with the oxalato complex fac-[Ru(dmso-S)(3)(dmso-O)(eta(2)-ox)] (9) yielded two asymmetric dimers, namely [{Ru([9]aneS(3))(dmso-S)}(mu-eta(4)-ox){fac-Ru(dmso-S)(3)(CF(3)SO(3))}][CF(3)SO(3)] (5) and [{Ru([9]aneS(3))(dmso-S)}(mu-eta(4)-ox){fac-Ru(dmso-S)(3)(dmso-O)}][CF(3)SO(3)](2) (6), depending on the reaction conditions. All new complexes were structurally characterized, both in solution (by NMR spectroscopy) and in the solid state (by X-ray crystallography). The chemical behavior of the complexes in aqueous solution was studied by UV-Vis and NMR spectroscopy in view of their potential antitumor activity: the monomers partially release a dmso ligand to yield the monofunctional aqua adduct [Ru([9]aneS(3))(eta(2)-dicarb)(H(2)O)], while the dimers rapidly open up the oxalato bridge to give two mononuclear fragments. Splitting of the asymmetric dimers 5 and 6 occurs selectively and the ox moiety remains bonded to the fac-Ru(dmso-S)(3) fragment. A detailed comparison of the structural and chemical features of 1-6 with those of similar dicarboxylate complexes possessing the fac-Ru(dmso-S)(3) fragment in place of Ru([9]aneS(3)) allows us to draw a number of general conclusions on the binding preferences of dicarb ligands on the octahedral Ru(II) center.

By connecting the siderophore aminochelin of Azotobacter vinelandii to a highly fluorescent tris(2,2Ј-bipyridyl)ruthenium(II)-type chromophore, a new modular sensor reagent has been synthesised and characterised, which selectively signals the presence of molybdate in solution through luminescence quenching.

No abstract